{"entity":{"id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","aka":["KUNPENG-3"],"tldr":"A phase 3 trial of Vebreltinib in non-small-cell lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, now recruiting.","summary":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive is a phase 3 interventional study registered as NCT06930794 by Beijing Pearl Biotechnology Limited Liability Company, with 300 participants planned, started 2025-07-07 and due to reach its primary completion in 2029-02. Interventions recorded: Vebreltinib combined with platinum-based doublet chemotherapy. and platinum-based doublet chemotherapy..","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06930794","url":"https://clinicaltrials.gov/study/NCT06930794"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["vebreltinib"],"companies":["beijing-pearl-biotechnology-limited-liability-company"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06930794","phase":"3","setting":"An Open-label, Randomized, Controlled, Multicenter Phase IIIb Clinical Study to Evaluate the Efficacy and Safety of Vebreltinib Enteric Capsule Combined With Platinum-based Doublet Chemotherapy Compared With Platinum-based Doublet Chemotherapy in Subjects With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Not Received Previous Systemic Treatment and MET-Positive","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","started":"2025-07-07","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06930794/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/"}]}}